Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing

Tacrolimus is the mainstay immunosuppressant drug used after solid organ and hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and intermediate metabolizers) generally have decreased dose‐adjusted trough concentrations of tacrolimus as compared with those who are CYP...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Pharmacol Ther
Autors principals: Birdwell, KA, Decker, B, Barbarino, JM, Peterson, JF, Stein, CM, Sadee, W, Wang, D, Vinks, AA, He, Y, Swen, JJ, Leeder, JS, van Schaik, RHN, Thummel, KE, Klein, TE, Caudle, KE, MacPhee, IAM
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2015
Matèries:
CPIC Guideline
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4481158/
https://ncbi.nlm.nih.gov/pubmed/25801146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.113
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars